Abstract
a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have